Galectin-1-mediated apoptosis in mycosis fungoides: The roles of CD7 and cell surface glycosylation

Modern Pathology

Volumn 16, Issue 6, 2003, Pages 543-551

  Roberts, Alice A ^a   Amano, Maho ^a   Felten, Christopher ^a   Galvan, Marisa ^a   Sulur, Giri ^a   Pinter Brown, Lauren ^a   Dobbeling, Udo ^b   Burg, Gunter ^b   Said, Jonathan ^a   Baum, Linda G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Apoptosis; CD7; Galectin; Glycosylation; Mycosis fungoides

Indexed keywords

CD7 ANTIGEN; GALECTIN 1;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; SEZARY CELL; T LYMPHOCYTE;

ANTIGENS, CD7; APOPTOSIS; CELL MEMBRANE; CELL SURVIVAL; FLOW CYTOMETRY; GALECTIN 1; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 0038118507     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000071840.84469.06     Document Type: Article

References (56)

1. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000;18:2908-25.
2. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
3. Zackheim HS, Vonderheid EC, Ramsay DL, LeBoit PE, Rothfleisch J, Kashani-Sabet M. Relative frequency of various forms of primary cutaneous lymphomas. J Am Acad Dermatol 2000;43:793-6.
4. Kim YH, Hoppe RT. Mycosis funguides and the Sezary syndrome. Semin Oncol 1999;26:276-89.
5. Burg G, Dummer R, Dommann S, Nestle F, Nickoloff B. Pathology of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:961-95.
6. Knowles DM. Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia. Am J Pathol 1989;134:761-85.
7. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999;135:26-32.
8. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 2002;3:193-215.
9. Duvic M, Cather JC. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol Clin 2000;18:147-56.
10. Van Haselen CW, Flens MJ, Scheper RJ, van der Valk P, Scheffer GL, Toonstra J, et al. Multidrug resistance related proteins in primary cutaneous lymphomas. Adv Exp Med Biol 1999;457:119-31.
11. Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol 2001; 145:928-37.
12. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001;98:2778-83.
13. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998;92:252-8.
14. Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol 1997;133:829-33.
15. Rabinovich GA. Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death Differ 1999;6: 711-22.
16. Liu FT. Galectins: a new family of regulators of inflammation. Clin Immunol 2000;97:79-88.
17. Cooper DN, Barondes SH. God must love galectins; he made so many of them. Glycobiology 1999;9:979-84.
18. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998;76:402-12.
19. Vespa GN, Lewis LA, Kozak KR, Moran M, Nguyen JT, Baum LG, et al. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol 1999;162:799-806.
20. Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med 1997;185:1851-8.
21. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995;378:736-9.
22. Ellerhorst J, Nguyen T, Cooper DN, Lotan D, Lotan R. Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int J Oncol 1999;14: 217-24.
23. Ellerhorst J, Nguyen T, Cooper DN, Estrov Y, Lotan D, Lotan R. Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1. Int J Oncol 1999;14:225-32.
24. Wells V, Davies D, Mallucci L. Cell cycle arrest and induction of apoptosis by beta galactoside binding protein (beta GBP) in human mammary cancer cells. A potential new approach to cancer control. Eur J Cancer 1999;35:978-83.
25. Kuwabara I, Kuwabara Y, Yand R-Y, Schuler M, Green DR, Zuraw BL, et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem 2002.;277:3487-97.
26. Berenerd F, Sarasin A, Magnaldo T. Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc Natl Acad Sci USA 1999;96:11329-34.
27. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol 2001;159:1055-60.
28. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000;85: 545-54.
29. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel andapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997;57: 5272-6.
30. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996; 93:6737-42.
31. Wollina U, Graefe T, Feldrappe S, Andre S, Wasano K, Kaltner H, et al. Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma. J Cancer Res Clin Oncol 2002;128:103-10.
32. Plzak J, Smetana K Jr, Hrdlickova E, Kodet R, Holikova Z, Liu FT, et al. Expression of galectin-3-reactive ligands in squamous cancer and normal epithelial cells as a marker of differentiation. Int J Oncol 2001;19:59-64.
33. Smetana K, Holikova Z, Klubal R, Bovin NV, Dvorankova B, Bartunkova J, et al. Coexpression of binding sites for A(B) histo-blood group trisaccharides with galectin-3 and Lag antigen in human Langerhans cells. J Leukoc Biol 1999;66: 644-9.
34. Akimoto Y, Hirabayashi J, Kasai K, Hirano H. Expression of the endogenous 14-kDa beta-galactoside-binding lectin galectin in normal human skin. Cell Tissue Res 1995;280:1-10.
35. Allen HJ, Sucato D, Gottstine S, Kisailus E, Nava H, Petrelli N, et al. Localization of endogenous beta-galactoside-binding lectin in human cells and tissues. Tumour Biol 1995;12:52-60.
36. Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. Cutting edge. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000;165:2331-4.
37. Pace KE, Lee C, Stewart PL, Baum LG. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 1999;163:3801-11.
38. Rappl G, Abken H, Muche JM, Sterry W, Tilgen W, Andre S, et al. CD4+CDT- leukemic T cells from patients with Sezary syndrome are protected from galectin-1-triggered T cell death. Leukemia 2002;16:840-5.
39. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002;99: 10231-3.
40. Baum LG, Pang M, Perillo NL, Wu T, Delegeane A, Uittenbogaart CH, et al. Human thymic epithelial cells express an endogenous lectin, galectin-1, which binds to core 2 O-glycans on thymocytes and T lymphoblastoid cells. J Exp Med 1995;181:877-87.
41. Gillespie W, Paulson JC, Kelm S, Pang M, Baum LG. Regulation of alpha 2,3-sialyltransferase expression correlates with conversion of peanut agglutinin (PNA)+ to PNA- phenotype in developing thymocytes. J Biol Chem 1993;268:3801-4.
42. Galvan M, Tsuboi S, Fukuda M, Baum LG. Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1. J Biol Chem 2000;275:16730-7.
43. Galvan M, Evans DP, Pace KE, Nguyen JT, Baum LG. Glycosylation controls T cell death induced by galectin-1 [abstract]. Glycobiology 2000;10:1087.
44. Brinck U, Korabiowska M, Bosbach R, Gabius HJ. Detection of inflammation- and neoplasia-associated alterations in human large intestine using plant/invertebrate lectins, galectin-1 and neoglycoproteins. Acta Anat 1998;161:219-33.
45. Baum LG, Derbin K, Perillo NL, Wu T, Pang M, Uittenbogaart C. Characterization of terminal sialic acid linkages on human thymocytes: correlation between lectin-binding phenotype and sialyltransferase expression. J Biol Chem 1996;271: 10793-9.
46. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001;409:733-9.
47. Braut-Boucher F, Font J, Pichon J, Paulin Y, Boukhelifa M, Aubery M, et al. T lymphocytes from Sezary syndrome patients express beta1 integrins whose beta(1-6)-branched N-linked oligosaccharides reflect their adhesive capacity. Leuk Res 1998;22:947-52.
48. Derappe C, Haentjens G, Lemaire S, Feugeas JP, Lebbe C, Pasqualetto V, et al. Circulating malignant lymphocytes from Sezary syndrome express high level of glycoproteins carrying beta (1-6)N-acetylglucosamine-branched N-linked oligosaccharides. Leukemia 1996;10:138-41.
49. Priatel JJ, Chui D, Hiraoka N, Simmons CJT, Richardson KB, Page DM, et al. The ST3Gal-I sialyltransferase controls CD8+ T lymphocyte homeostasis by modulating O-glycan biosynthesis. Immunity 2000;12:273-83.
50. Galvan M, Murali-Krishna K, Ming LL, Baum L, Ahmed R. Alterations in cell surface carbohydrates on T cells from virally infected mice can distinguish effector/memory CD8+ T cells from naive cells. J Immunol 1998;161:641-8.
51. Di Virgilio S, Glushka J, Moremen K, Pierce M. Enzymatic synthesis of natural and 13C enriched linear poly-N-acetyllactosamines as ligands for galectin-1. Glycobiology 1999;9:353-64.
52. Salvatore P, Benvenuto G, Pero R, Lembo F, Bruni CB, Chiariotti L. Galectin-1 gene expression and methylation state in human T leukemia cell lines. Int J Oncol 2000;17: 1015-8.
53. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001;7:2682-92.
54. Zietz C, Rumpler U, Sturzl M, Lohrs U. Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack. Am J Pathol 2001;159:963-70.
55. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. Dis Esophagus 1999;12:83-9.
56. Bernengo MG, Quaglino P, Novelli M, Cappello N, Doveil GC, Lisa F, et al. Prognostic factors in Sezary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998;9:857-63.